# Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma

> **NCT00003719** · PHASE2 · UNKNOWN · sponsor: **Herbert Irving Comprehensive Cancer Center** · enrollment: 27 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003719
- **Lead sponsor:** Herbert Irving Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003719, "Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00003719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*